Virax Biolabs (US:VRAX) Prnewswire·2025-07-18 20:15Core Points - Virax Biolabs Group Limited has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share [1][2] - The company has a compliance period of 180 calendar days, until January 12, 2026, to regain compliance [3] - If the closing bid price reaches at least $1.00 for 10 consecutive business days during this period, Nasdaq will confirm compliance [3] - The notification does not lead to immediate delisting, and shares will continue to trade under the symbol "VRAX" [4] Company Overview - Virax Biolabs Group Limited is focused on the detection of immune responses and diagnosis of viral diseases [4] - The company is developing T-Cell-based test technologies aimed at providing an immunology profiling platform [4] - T-Cell testing is particularly effective for diagnosing post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation [4]